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Table 1
Suppression capability of Class I and Class II aaRS on mt tRNA mutants aminoacylated by Class I mt aaRS.
Glycerol growth of transformant strains
Class I aaRS Class II aaRS
tRNA mutant tRNA defect Glycerol
growth
LeuRS ValRS IleRS
(ISM1)
Ia
GluRS
(MSE1)
or
Cyt GlnRS
(GLN4)
TyrRS
(MSY1)
Ic
GlyRS, HisRS,
AspRS, LysRS,
PheRS
Sc
(NAM2)
Ia
Hs
(LARS2)
Ia
Sc
(VAS1)
Ia
Hs
(VARS2)
Ia
28 °C 37 °C
VAL C25T
[14]
Low amount
of tRNAVal
+/– +/– + + + + + + + + + + +/– +/– + + +/– +/–
[29] [29] [14,29] [29]
LEU A14G
[17]
Aminoacylation
defect
– – + + + + + + + + + + – – – – – –
[38]
LEU C25T
[17]
No tRNAs – – + + + + + + + + + + – – – – – –
[14,29,38] [29] [29] [29]
ILE T32C
[18]
No tRNAs – – + + + + + + + + + + – – – – – –
[18] [18] [18]
GLN C6T
[40]
Structural and
aminoacylation
defects
+/– – + + + – +/– – +/– – +/– – +/– – +/– – +/– –
+ indicates growth similar to wild type; – indicates absence of growth; +/– indicates partial growth.
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Table 2
Suppression capability of Class I and Class II aaRS on mt tRNA mutants normally aminoacylated by class II mt aaRS.
Glycerol growth of transformant strains
Class I aaRS Class II aaRS
tRNA
mutant
tRNA defect Glycerol growth LeuRS ValRS IleRS
(ISM1)
Ia
GluRS
(MSE1)
or
Cyt
GlnRS
(GLN4)
Ib
TyrRS
(MSY1)
Ic
GlyRS
(GRS1)
IIa
HisRS
(HTS1)
IIa
AspRS
(MSD1)
IIb
LysRS
(MSK1)
IIb
PheRS
(MSF1)
IIc
Sc
(NAM2)
Ia
Hs
(LARS2)
Ia
Sc
(VAS1)
Ia
Hs
(VARS2)
Ia
28 °C 37 °C
ASP C61T
[21]
3′ end processing – – – – + – – – +/– – + – – – – – – – + – + + + – + –
[38] [27]
GLY G30T
[19]
No tRNAs – – – – – – – – – – – – – – – – – – – – – – – – – –
HIS G51A
[40]
Structural defect +/– – +/– – + – +/– +/– + – + – +/– – + + + + + + +/– – + + + +
[38]
PHE C2T
[20]
Ternary complex
formation
+ – + – + – + – + – + – + – + – + – + – + – + – + –
PHE C62T
[20]
3′ end processing – – – – – – – – – – – – – – – – – – – – – – – – – –
+ indicates growth similar to wild type; – indicates absence of growth; +/– indicates partial growth.
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Table 3
Suppression capability of carboxy-terminal domain of mt LeuRS, and the corresponding “Cterm” region of mt ValRS and mt IleRS.
tRNA mutants Glycerol growth Glycerol growth of transformant strains
28 °C 37 °C Cterm
(NAM2)
Cterm
(LARS2)
β30_31
(LARS2)
β32_33
(LARS2)
“Cterm”
(VARS2)
“Cterm”
(IARS2)
tRNA aminoacylated
by Class I aaRS
GLN C6T +/– – + – + – + – + – +/– – +/– –
VAL C25T +/– +/– + + + + + + + + + + + +
[7] [7] [7]
LEU A14G – – + + + + + + + + – – – –
LEU C25T – – + + + + + + + + – – – –
[7]
ILE T32C – – + + – – + + + + – – – –
[7]
tRNA aminoacylated
by Class II aaRS
ASP C61T – – + – + – + – + – – – – –
GLY G30A – – – – – – – – – – – – – –
HIS G51A +/– – + + + + ++ ++ ++ ++ + +/– +/– –
PHE C2T + – + – + – ++ + ++ + + – + –
PHE C62T – – – – – – – – – – – – – –
“Cterm” is the carboxy-terminal domain of the human mt ValRS and IleRS aligned with the suppressing Cterm domain of human mt LeuRS.
+ indicates growth similar to wild type; – indicates absence of growth; +/– indicates partial growth.
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